Last reviewed 2026-05-14 · How we verify

MenABCWY vaccine

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Administration site pain
• Fatigue
• Headache
• Myalgia
• Nausea
• Arthralgia
• Injection site pain
• COVID-19
• Administration site induration
• Administration site erythema
• Swelling
• Erythema

Key clinical trials

• Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents (PHASE2)
• A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules (PHASE2)
• Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine (PHASE3)
• A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (PHASE2)
• Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults (PHASE3)
• A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
• MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (PHASE3)
• A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MenABCWY vaccine CI brief — competitive landscape report
• MenABCWY vaccine updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI